@article{47ac64abf1524c64875107385f1ceccf,
title = "Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat",
abstract = "YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.",
keywords = "Adipokines, Adult, Aged, Aged, 80 and over, C-Reactive Protein, Female, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Lectins, Male, Middle Aged, Polycythemia Vera, Thrombocythemia, Essential",
author = "Andersen, {Christen Lykkegaard} and Bj{\o}rn, {Mads Emil} and McMullin, {Mary Frances} and Claire Harrison and Jan Samuelsson and Elisabeth Ejerblad and Sonja Zweegman and Savio Fernandes and David Bareford and Steven Knapper and Eva L{\"o}fvenberg and Olle Linder and Bj{\o}rn Andreasson and Erik Ahlstrand and Jensen, {Morten Krogh} and Bjerrum, {Ole Weis} and Hanne Vestergaard and Herdis Larsen and Klausen, {Tobias Wirenfeldt} and Torben Mourits-Andersen and Vibe Skov and Mads Thomassen and Torben Kruse and Kirsten Gr{\o}nb{\ae}k and Hasselbalch, {Hans Carl}",
note = "Copyright {\textcopyright} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
doi = "10.1016/j.leukres.2014.04.002",
language = "English",
volume = "38",
pages = "816--821",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier",
number = "7",
}